MedTrace Logo

Open-label Study of CS-1008 for Subjects With Untreated and Unresectable Pancreatic Cancer

NCT00521404 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 65

Last updated 2021-04-08

Study results available
· View outcomes & findings →

Summary

Phase 2 study to determine the efficacy and safety of CS-1008 when given with gemcitabine to subjects with previously untreated and unresectable (unable to be surgically removed) or metastatic (spread to other areas beyond the pancreas) pancreatic cancer.

Conditions

Interventions

DRUG

CS-1008 (humanized anti-DR5 antibody)

CS-1008: 8mg/kg loading dose followed by 3mg/kg weekly.

DRUG

gemcitabine

Gemcitabine - 1000mg/meter sq

Sponsors & Collaborators

Principal Investigators

  • Global Clinical Leader · Daiichi Sankyo

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2007-08-15
Primary Completion
2010-08-20
Completion
2010-08-20

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00521404 on ClinicalTrials.gov